Muscarinic Receptor Occupancy and Cognitive Impairment: a PET Study with [11C](+)3-MPB and Scopolamine in Conscious Monkeys
Overview
Authors
Affiliations
The muscarinic cholinergic receptor (mAChR) antagonist scopolamine was used to induce transient cognitive impairment in monkeys trained in a delayed matching to sample task. The temporal relationship between the occupancy level of central mAChRs and cognitive impairment was determined. Three conscious monkeys (Macaca mulatta) were subjected to positron emission tomography (PET) scans with the mAChR radioligand N-[(11)C]methyl-3-piperidyl benzilate ([(11)C](+)3-MPB). The scan sequence was pre-, 2, 6, 24, and 48 h post-intramuscular administration of scopolamine in doses of 0.01 and 0.03 mg/kg. Occupancy levels of mAChR were maximal 2 h post-scopolamine in cortical regions innervated primarily by the basal forebrain, thalamus, and brainstem, showing that mAChR occupancy levels were 43-59 and 65-89% in doses of 0.01 and 0.03 mg/kg, respectively. In addition, dose-dependent impairment of working memory performance was measured 2 h after scopolamine. A positive correlation between the mAChR occupancy and cognitive impairment 2 and 6 h post-scopolamine was the greatest in the brainstem (P<0.00001). Although cognitive impairment was not observed 24 h post-scopolamine, sustained mAChR occupancy (11-24%) was found with both doses in the basal forebrain and thalamus, but not in the brainstem. These results indicate that a significant degree of mAChRs occupancy is needed to produce cognitive impairment by scopolamine. Furthermore, the importance of the brainstem cholinergic system in working memory in monkey is described.
Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography.
Zhang J, Fu H, Lin R, Zhou J, Haider A, Fang W J Med Chem. 2023; 66(16):10889-10916.
PMID: 37583063 PMC: 10461233. DOI: 10.1021/acs.jmedchem.3c00573.
PET Imaging in Animal Models of Alzheimer's Disease.
Chen B, Marquez-Nostra B, Belitzky E, Toyonaga T, Tong J, Huang Y Front Neurosci. 2022; 16:872509.
PMID: 35685772 PMC: 9171374. DOI: 10.3389/fnins.2022.872509.
Ni R Pharmaceuticals (Basel). 2021; 14(11).
PMID: 34832961 PMC: 8623863. DOI: 10.3390/ph14111179.
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease.
Iarkov A, Mendoza C, Echeverria V Front Neurosci. 2021; 15:665820.
PMID: 34616271 PMC: 8488354. DOI: 10.3389/fnins.2021.665820.
PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain.
Smart K, Naganawa M, Baldassarri S, Nabulsi N, Ropchan J, Najafzadeh S Cereb Cortex. 2021; 31(6):2787-2798.
PMID: 33442731 PMC: 8355478. DOI: 10.1093/cercor/bhaa387.